Stock Taper
SCREENER COMPARE ANY 2 STOCKS
TNGX
TANGO THERAPEUTICS, INC.
NASDAQ
$23.34
▼ DOWN 7.67% (-1.94)

KEY STATISTICS

Market Cap$3.80 B
52w High$34.39
52w Low$6.25
Dividend Yield—
Frequency—
P/E-28.12
Volume2.00M
Shares Out.162.81M

COMPANY

LEADERSHIP

Malte Peters
CHIEF EXECUTIVE
Malte Peters

COMPENSATION 2026

Salary$659,996
Stock Awards$1,070,423
Incentive Plan Pay$447,477
All Other Comp.$18,016
Total$6,541,200

ABOUT

SECTOR
Healthcare
WENT PUBLIC
September 3, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
137

PRICE TARGET

Target High$69.00
Target Low$24.00
Target Median$40.00
Target Consensus$45.91

UPCOMING EARNINGS

DateNov 3, 2026
DayTuesday
Rev. Est.$3.28M
NOV
3
TUE

PRICE

$23.34 ▼ DOWN 7.67% (−$1.94)
$23.25$24.00$24.759:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM23.34

About Tango Therapeutics, Inc.

https://www.tangotx.com ↗

Tango Therapeutics, founded in 2017 in Cambridge, MA, develops cancer treatments including TNG908, a methyltransferase inhibitor, and collaborates with Gilead on innovative oncology therapies.

INDUSTRY

Biotechnology

A PRODUCT TANGO THERAPEUTICS, INC. IS KNOWN FOR

Vopimetostat (TNG462)
Vopimetostat (TNG462)

Vopimetostat is Tango Therapeutics' investigational PRMT5 inhibitor targeting MTAP-deleted solid tumors, with a pivotal trial planned for pancreatic cancer.

COMPETITORS

COMPETITOR
AMGN COMPARE
IDYA COMPARE
KYMR COMPARE
PRLD COMPARE
RVMD COMPARE

Revenue by Products

IconPRODUCTQ1-2025Q2-2025Q3-2025Q4-2025
Collaboration Revenue$5.39M $3.18M ▼$53.81M ▲$0 ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
138
LISTED HERE
26
RANKED BY POSITION SIZE
VTS.AX
0.01% · 4.4M
XSU.TO
0.11% · 3.6M
XBI
0.65% · 3.1M
SCHA
0.06% · 589.6K
FESM
0.16% · 405.8K
FYC
0.42% · 243.0K
DWAS
1.21% · 207.6K
TMSL
0.14% · 173.3K
DFMC
0.05% · 154.0K
XRS2.F
0.11% · 128.0K
USVM
0.18% · 124.3K
LABU
0.44% · 111.8K
NUSC
0.15% · 89.4K
CANC
0.90% · 82.0K
RSSL
0.11% · 67.2K
GSSC
0.09% · 38.8K
AVSC
0.03% · 37.8K
BBSC
0.09% · 26.9K
FSCC
0.09% · 12.6K
BBC
0.49% · 10.1K
ETLZ.DE
0.09% · 7.9K
URTY
0.04% · 5.7K
ACSG
0.27% · 5.6K
SGRW
0.38% · 4.5K
BKSE
0.11% · 4.4K
RFLR
0.07% · 2.8K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
86.56%
HOLDERS
311
TOP 12 OF 311 · RANKED BY POSITION SIZE
Rtw Investments, LP
13.9M sh · $434.53M
Trv Gp Iv, LLC
13.9M sh · $116.46M
Farallon Capital Management LLC
13.1M sh · $115.72M
Adage Capital Partners Gp, L.L.C.
12.8M sh · $267.97M
Tcg Crossover Management, LLC
12.8M sh · $113.07M
Blackrock, Inc.
12.4M sh · $388.83M
Fmr LLC
12.3M sh · $385.54M
Boxer Capital Management, LLC
10.9M sh · $96.36M
Ecor1 Capital, LLC
10.6M sh · $89.3M
Woodline Partners LP
10.1M sh · $89.24M
Goldman Sachs Group Inc
10.0M sh · $311.99M
Boxer Capital, LLC
8.2M sh · $63.13M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
OFFICER: PRESIDENT, R&D
Crystal Adam
Sale · 21.7K shares
2026-08-03
★
OFFICER: PRESIDENT, R&D
Crystal Adam
Sale · 27.0K shares
2026-08-03
★
OFFICER: PRESIDENT, R&D
Crystal Adam
Purchase · 27.0K shares
2026-08-03
★
OFFICER: PRESIDENT, R&D
Crystal Adam
Sale · 5.3K shares
2026-08-03

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 6
OUTPERFORM 3
NEUTRAL 1
10 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY Guggenheim BUY Mizuho OUTPERFORM Canaccord Genuity BUY Jefferies BUY Leerink Partners OUTPERFORM Piper Sandler NEUTRAL Wedbush OUTPERFORM

SECTORS PEERS

PEERPRICE
NRIX$26.21COMPARE
KOD$37.72COMPARE
URGN$43.62COMPARE
XNCR$26.06COMPARE
FTRE$18.81COMPARE
SEPN$38.91COMPARE
BCAX$23.43COMPARE
KURA$12.66COMPARE